H.C. Wainwright analyst Ed Arce downgraded Iterum Therapeutics (NASDAQ: ITRM) from Buy to Neutral following the CRL.The analyst commented, "This ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE